Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal

作者: Rocio Sotillo , Juan-Manuel Schvartzman , Nicholas D. Socci , Robert Benezra

DOI: 10.1038/NATURE08803

关键词: AneuploidyChromosome instabilityOncogene AddictionOncogeneBiologyCancerMad2Cancer researchKRASMitosis

摘要: Inhibition of an initiating oncogene often leads to extensive tumour cell death, a phenomenon known as addiction. This has led the search for compounds that specifically target and inhibit oncogenes anticancer agents. However, there been no systematic exploration whether chromosomal instability generated result deregulation mitotic checkpoint pathway, frequent characteristic solid tumours, any effect on Here we show induction chromosome by overexpression gene Mad2 in mice does not affect regression Kras-driven lung tumours when Kras is inhibited. experience transient consequent recur at markedly elevated rates. The recurrent are highly aneuploid have varied activation pro-proliferative pathways. Thus, early may be responsible relapse after seemingly effective treatments.

参考文章(28)
Lynda Chin, Alice Tam, Jason Pomerantz, Michelle Wong, Jocelyn Holash, Nabeel Bardeesy, Qiong Shen, Ronan O'Hagan, Joe Pantginis, Hao Zhou, James W. Horner, Carlos Cordon-Cardo, George D. Yancopoulos, Ronald A. DePinho#, Essential role for oncogenic Ras in tumour maintenance Nature. ,vol. 400, pp. 468- 472 ,(1999) , 10.1038/22788
Michael E. O'Dwyer, Michael J. Mauro, Gwen Kurilik, Motomi Mori, Suzanne Balleisen, Susan Olson, Ellen Magenis, Renaud Capdeville, Brian J. Druker, The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML Blood. ,vol. 100, pp. 1628- 1633 ,(2002) , 10.1182/BLOOD-2002-03-0777
Jorge Cortes, Michael E O'Dwyer, Clonal evolution in chronic myelogenous leukemia. Hematology-oncology Clinics of North America. ,vol. 18, pp. 671- 684 ,(2004) , 10.1016/J.HOC.2004.03.012
Darren J Baker, Junjie Chen, Jan MA van Deursen, The mitotic checkpoint in cancer and aging: what have mice taught us? Current Opinion in Cell Biology. ,vol. 17, pp. 583- 589 ,(2005) , 10.1016/J.CEB.2005.09.011
Eva Hernando, Zaher Nahlé, Gloria Juan, Elena Diaz-Rodriguez, Miguel Alaminos, Michael Hemann, Loren Michel, Vivek Mittal, William Gerald, Robert Benezra, Scott W. Lowe, Carlos Cordon-Cardo, Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control Nature. ,vol. 430, pp. 797- 802 ,(2004) , 10.1038/NATURE02820
Robert B. Boxer, Joanne W. Jang, Louis Sintasath, Lewis A. Chodosh, Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. ,vol. 6, pp. 577- 586 ,(2004) , 10.1016/J.CCR.2004.10.013
C. V. Rao, Y.-M. Yang, M. V. Swamy, T. Liu, Y. Fang, R. Mahmood, M. Jhanwar-Uniyal, W. Dai, Colonic tumorigenesis in BubR1+/–ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 4365- 4370 ,(2005) , 10.1073/PNAS.0407822102
Mercedes E Gorre, Mansoor Mohammed, Katharine Ellwood, Nicholas Hsu, Ron Paquette, P Nagesh Rao, Charles L Sawyers, Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification Science. ,vol. 293, pp. 876- 880 ,(2001) , 10.1126/SCIENCE.1062538
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238